摘要目的观察地特胰岛素联合瑞格列奈治疗对新诊断2型糖尿病（T2DM）患者的效果及对血尿酸（UA）水平的影响。方法选择2016年1～6月于我院就诊的新诊断的糖化血红蛋白（HbA1c）≥8.5%的T2DM患者36例，所有患者给予地特胰岛素联合瑞格列奈治疗12周，比较治疗前后血清UA、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、HbA1c、血脂、体重、空腹胰岛素水平（FINS），计算胰岛素抵抗指数（HOMA-IR）和胰岛素敏感指数（ISI）。结果与治疗前比较，治疗后ISI由（7.02±3.48）显著升至（7.83±3.39）（P<0.05），FPG、2 h PG、UA、TG、HbA1c、HOMA-IR显著降低（P<0.05），体重、FINS无明显变化（P>0.05）。结论地特胰岛素联合瑞格列奈治疗可有效改善新诊断T2DM患者的胰岛素抵抗，降低血UA水平。
ObjectiveTo explore the Influence of Insulin Determir combined with Repaglinide therapy on serum uric (UA)acid of newly diagnosed type 2 diabetic patients.MethodsA total of 36 newly diagnosed type 2 diabetic patients with HbA1c≥8.5% receivedInsulin Determir combined with Repaglinide therapy for 12 weeks in our hospital from Janurary to June 2016 were selected.A comparison on UA,fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG), HbA1c,blood lipid,body weight,fasting insulin(FINS),homa-insulin resistance(Homa-IR)and insulin sensitivity index(ISI) were performed before and after the treatment.ResultsCompared with before treatment,ISI was significantly increased from(7.02±3.48)to(7.83±3.39)(P<0.05),UA,FPG,2 h PG,HbA1c,TG,LDL-C and Homa-IR were significantly decreased after the treatment(P<0.05),and while body weight and FINS had no statistically significant difference before and after the treatment(P>0.05).ConclusionInsulin Determir combined with Repaglinide therapy can effectively improve the insulin resistance and decrease level of serum UA in the newly diagnosed type 2 diabetic patients.
Hirsch IB.Intensifying insulin therapy in patients with type 2 diabetes mellitus[J].Am J Med，2005，118（5）：21s-26s.
[11]
Raskin P，Gylvin T，Weng W，et al.Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized，controlled clinical study in patients with type 2 diabetes[J].Diabetes Metab Res Rev，2009，25（6）：542-548.
京公网安备 11010502046607号